Pure Global
NCT06362044

A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan

The Frequency of uMRD in Japanese Patients With CLL After 24 Months of Treatment With Venetoclax±Rituximab in the 2L+ in the Real-World Setting
AbbVie·ClinicalTrials.govRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Lymphocytic Leukemia
Study type
Observational
Sponsor & location
Primary sponsor
AbbVie
Location
Kashiwa, Japan
Timeline & enrollment
Phase
N/A
Start date
Jun 07, 2023
End date
Dec 31, 2024
Enrollment
89 participants
Primary outcome

Percentage of Participants with Undetectable Minimal Residual Disease (uMRD)

Summary

Most cases of Chronic lymphocytic leukemia (CLL) remain an incurable disease with the goal of
 therapy being to improve quality of life and to prolong survival. This study will evaluate
 the participant's related outcomes and experience of CLL in adult participants who are
 treated in the Japan.
 
 Study participants will receive oral treatments of Venetoclax±Rituximab for CLL as prescribed
 by their study doctor in accordance with approved local label. Adult participants prescribed
 various treatments Venetoclax±Rituximab will be enrolled. Around 89 participants will be
 enrolled in the study in sites in Japan.
 
 Participants will receive oral venetoclax tablets ± intravenously (IV) infused rituximab
 treatments for CLL according to the approved local label. The overall study duration will be
 27 months.
 
 There is expected to be no additional burden for participants in this trial. All study visits
 will occur during routine clinical practice.

ICD-10 classifications
Chronic lymphocytic leukaemia of B-cell typeChronic myelomonocytic leukaemiaAcute myelomonocytic leukaemiaLymphoid leukaemiaChronic leukaemia of unspecified cell type
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06362044
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06362044 through Pure Global AI's free database. This phase not specified trial is sponsored by AbbVie and is currently Recruiting. The study focuses on Chronic Lymphocytic Leukemia. Target enrollment is 89 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.